Covalon Technologies Ltd. (COV.V)
CAD 3.44
(2.99%)
CAD 3.44
(2.99%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 5.94 Million CAD | 19.71% |
| 2022 | 4.96 Million CAD | 5.6% |
| 2021 | 4.7 Million CAD | -34.69% |
| 2020 | 7.19 Million CAD | -14.95% |
| 2019 | 8.46 Million CAD | 52.13% |
| 2018 | 5.56 Million CAD | 124.6% |
| 2017 | 2.47 Million CAD | 21.67% |
| 2016 | 2.03 Million CAD | 143.46% |
| 2015 | 836.36 Thousand CAD | 53.39% |
| 2014 | 545.26 Thousand CAD | -10.01% |
| 2013 | 605.89 Thousand CAD | -24.83% |
| 2012 | 806.01 Thousand CAD | 105.41% |
| 2011 | 392.38 Thousand CAD | 67.21% |
| 2010 | 234.66 Thousand CAD | -31.3% |
| 2009 | 341.58 Thousand CAD | 22.76% |
| 2008 | 278.25 Thousand CAD | -0.38% |
| 2007 | 279.33 Thousand CAD | 3.69% |
| 2006 | 269.39 Thousand CAD | 109.77% |
| 2005 | 128.42 Thousand CAD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 6.74 Million CAD | 18.63% |
| 2024 Q2 | 5.68 Million CAD | -5.98% |
| 2024 Q1 | 6.04 Million CAD | 1.76% |
| 2023 Q1 | 6.54 Million CAD | 31.79% |
| 2023 Q2 | 6.92 Million CAD | 5.85% |
| 2023 Q3 | 7.58 Million CAD | 9.46% |
| 2023 FY | 5.94 Million CAD | 19.71% |
| 2023 Q4 | 5.94 Million CAD | -21.6% |
| 2022 FY | 4.96 Million CAD | 5.6% |
| 2022 Q2 | 4.79 Million CAD | 16.01% |
| 2022 Q3 | 4.95 Million CAD | 3.51% |
| 2022 Q1 | 4.12 Million CAD | -12.19% |
| 2022 Q4 | 4.96 Million CAD | 0.15% |
| 2021 Q4 | 4.7 Million CAD | -15.43% |
| 2021 Q1 | 6.93 Million CAD | -3.7% |
| 2021 Q2 | 6.34 Million CAD | -8.43% |
| 2021 Q3 | 5.55 Million CAD | -12.44% |
| 2021 FY | 4.7 Million CAD | -34.69% |
| 2020 Q3 | 9.15 Million CAD | -6.94% |
| 2020 Q2 | 9.84 Million CAD | 6.4% |
| 2020 FY | 7.19 Million CAD | -14.95% |
| 2020 Q1 | 9.25 Million CAD | 9.27% |
| 2020 Q4 | 7.19 Million CAD | -21.39% |
| 2019 Q3 | 8.81 Million CAD | -13.81% |
| 2019 FY | 8.46 Million CAD | 52.13% |
| 2019 Q2 | 10.23 Million CAD | 1.58% |
| 2019 Q1 | 10.07 Million CAD | 81.0% |
| 2019 Q4 | 8.46 Million CAD | -4.0% |
| 2018 Q3 | 4.01 Million CAD | 18.42% |
| 2018 Q1 | 2.93 Million CAD | 18.33% |
| 2018 FY | 5.56 Million CAD | 124.6% |
| 2018 Q4 | 5.56 Million CAD | 38.65% |
| 2018 Q2 | 3.38 Million CAD | 15.61% |
| 2017 Q1 | 1.85 Million CAD | -9.01% |
| 2017 FY | 2.47 Million CAD | 21.67% |
| 2017 Q4 | 2.47 Million CAD | 0.03% |
| 2017 Q3 | 2.47 Million CAD | 52.94% |
| 2017 Q2 | 1.61 Million CAD | -12.59% |
| 2016 Q3 | 1.69 Million CAD | -15.04% |
| 2016 Q2 | 1.98 Million CAD | 36.61% |
| 2016 Q4 | 2.03 Million CAD | 20.47% |
| 2016 FY | 2.03 Million CAD | 143.46% |
| 2016 Q1 | 1.45 Million CAD | 74.12% |
| 2015 Q1 | 683.35 Thousand CAD | 25.33% |
| 2015 Q4 | 836.36 Thousand CAD | 11.01% |
| 2015 FY | 836.36 Thousand CAD | 53.39% |
| 2015 Q2 | 772.69 Thousand CAD | 13.07% |
| 2015 Q3 | 753.42 Thousand CAD | -2.49% |
| 2014 FY | 545.26 Thousand CAD | -10.01% |
| 2014 Q1 | 703.42 Thousand CAD | 16.1% |
| 2014 Q3 | 809.98 Thousand CAD | -6.61% |
| 2014 Q4 | 545.26 Thousand CAD | -32.68% |
| 2014 Q2 | 867.34 Thousand CAD | 23.3% |
| 2013 Q1 | 829.63 Thousand CAD | 2.93% |
| 2013 Q4 | 605.89 Thousand CAD | -37.13% |
| 2013 FY | 605.89 Thousand CAD | -24.83% |
| 2013 Q3 | 963.79 Thousand CAD | -9.98% |
| 2013 Q2 | 1.07 Million CAD | 29.04% |
| 2012 Q3 | 583.99 Thousand CAD | 25.32% |
| 2012 Q2 | 465.99 Thousand CAD | 7.28% |
| 2012 Q1 | 434.38 Thousand CAD | 10.7% |
| 2012 FY | 806.01 Thousand CAD | 105.41% |
| 2012 Q4 | 806.01 Thousand CAD | 38.02% |
| 2011 FY | 392.38 Thousand CAD | 67.21% |
| 2011 Q4 | 392.38 Thousand CAD | 17.32% |
| 2011 Q3 | 334.45 Thousand CAD | -12.63% |
| 2011 Q2 | 382.78 Thousand CAD | 26.84% |
| 2011 Q1 | 301.79 Thousand CAD | 28.6% |
| 2010 Q3 | 127.41 Thousand CAD | -33.07% |
| 2010 Q4 | 234.66 Thousand CAD | 84.18% |
| 2010 FY | 234.66 Thousand CAD | -31.3% |
| 2010 Q1 | 291.15 Thousand CAD | -14.76% |
| 2010 Q2 | 190.36 Thousand CAD | -34.62% |
| 2009 Q4 | 341.58 Thousand CAD | -7.9% |
| 2009 Q3 | 370.89 Thousand CAD | -19.0% |
| 2009 Q2 | 457.91 Thousand CAD | 19.74% |
| 2009 Q1 | 382.42 Thousand CAD | 37.44% |
| 2009 FY | 341.58 Thousand CAD | 22.76% |
| 2008 Q2 | 249.78 Thousand CAD | 33.99% |
| 2008 Q4 | 278.25 Thousand CAD | 9.67% |
| 2008 Q3 | 253.71 Thousand CAD | 1.57% |
| 2008 FY | 278.25 Thousand CAD | -0.38% |
| 2008 Q1 | 186.41 Thousand CAD | -33.26% |
| 2007 Q3 | 359.2 Thousand CAD | -1.15% |
| 2007 FY | 279.33 Thousand CAD | 3.69% |
| 2007 Q1 | 320.31 Thousand CAD | 18.9% |
| 2007 Q4 | 279.33 Thousand CAD | -22.24% |
| 2007 Q2 | 363.39 Thousand CAD | 13.45% |
| 2006 Q3 | 202.71 Thousand CAD | 24.41% |
| 2006 Q2 | 162.93 Thousand CAD | -29.94% |
| 2006 Q1 | 232.57 Thousand CAD | 81.09% |
| 2006 Q4 | 269.39 Thousand CAD | 32.9% |
| 2006 FY | 269.39 Thousand CAD | 109.77% |
| 2005 FY | 128.42 Thousand CAD | 0.0% |
| 2005 Q1 | - CAD | 0.0% |
| 2005 Q2 | 105.82 Thousand CAD | 0.0% |
| 2005 Q4 | 128.42 Thousand CAD | 21.1% |
| 2005 Q3 | 106.05 Thousand CAD | 0.22% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Arch Biopartners Inc. | - CAD | -Infinity% |
| Hemostemix Inc. | - CAD | -Infinity% |
| Universal Ibogaine Inc. | - CAD | -Infinity% |
| Kane Biotech Inc. | 250.41 Thousand CAD | -2273.854% |
| MedMira Inc. | 182.42 Thousand CAD | -3158.636% |
| Marvel Biosciences Corp. | - CAD | -Infinity% |
| NervGen Pharma Corp. | - CAD | -Infinity% |
| XORTX Therapeutics Inc. | - CAD | -Infinity% |